Thermo Fisher and IBI Team Up to Bring MSIA Technology Into the Clinic
July 16, 2010
Thermo Fisher and IBI Team Up to Bring MSIA Technology Into the Clinic
The collaboration aims to turn IBI's mass-spec immunoassay technology from a tool it has offered exclusively on a contract-research basis into a turnkey product available to clinical research laboratories around the world.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Thermo Fisher Acquires Proteomics Firm Intrinsic Bioprobes
September 2, 2011 / ProteoMonitor - 26,000-Patient Study Suggests Triple-Biomarker Approach Could Improve CKD Diagnosis
April 29, 2011 / ProteoMonitor - Top-Down Proteomics Inching Its Way Toward the Mainstream
April 8, 2011 / ProteoMonitor - Intrinsic Bioprobes Receives US Patent for Protein Biomarkers for Myocardial Infarction
October 29, 2010 / ProteoMonitor - Merck Sees Promise for Mass Spec-Based Protein Biomarker Pipeline in Drug Development
October 8, 2010 / ProteoMonitor